Influence of virulence genotype and resistance profile in the mortality of pseudomonas aeruginosa bloodstream infections

Clinical Infectious Diseases

Volumn 60, Issue 4, 2015, Pages 539-548

  Pea, Carmen ^a   Cabot, Gabriel ^b   Gómez Zorrilla, Silvia ^a   Zamorano, Laura ^b   Ocampo Sosa, Alain ^c   Murillas, Javier ^b   Almirante, Benito ^d   Pomar, Virginia ^e   Aguilar, Manuela ^f   Granados, Ana ^g   Calbo, Esther ^h   Rodríguez Bão, Jesús ⁱ   Rodríguez López, Fernando ^j   Tubau, Fe ^a   Martínez Martínez, Luis ^c,k   Oliver, Antonio ^b  

^a HOSPITAL UNIVERSITARI DE BELLVITGE   (Spain)

^b HOSPITAL UNIVERSITARIO SON ESPASES   (Spain)

^c HOSPITAL UNIVERSITARIO MARQUÉS DE VALDECILLA   (Spain)

^d HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

^e HOSPITAL DE LA SANTA CREU I SANT PAU   (Spain)

^f HOSPITAL UNIVERSITARIO VIRGEN DEL ROCÍO   (Spain)

^g Department of Pediatrics   (Spain)

^h HOSPITAL MÚTUA DE TERRASSA   (Spain)

ⁱ HOSPITAL UNIVERSITARIO VIRGEN MACARENA   (Spain)

^j HOSPITAL UNIVERSITARIO REINA SOFÍA   (Spain)

^k UNIVERSITY OF CANTABRIA   (Spain)

more..

Author keywords

bloodstream infections; multidrug resistance; Pseudomonas aeruginosa; type III secretion system; virulence

Indexed keywords

ADULT; AGED; ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIAL VIRULENCE; BLOODSTREAM INFECTION; CLINICAL ASSESSMENT; DISEASE ASSOCIATION; FEMALE; GENE INTERACTION; GENETIC ASSOCIATION; GENOTYPE; HUMAN; INFECTION CONTROL; MAJOR CLINICAL STUDY; MALE; MORTALITY; MULTICENTER STUDY; MULTIDRUG RESISTANCE; OUTCOME ASSESSMENT; PHENOTYPIC VARIATION; POST HOC ANALYSIS; PRIORITY JOURNAL; PROSPECTIVE STUDY; PSEUDOMONAS AERUGINOSA; SURVIVAL RATE; TYPE III SECRETION SYSTEM; BACTEREMIA; BACTERIAL SECRETION SYSTEM; CLINICAL TRIAL; DRUG EFFECTS; GENETICS; ISOLATION AND PURIFICATION; MICROBIOLOGY; MIDDLE AGED; MULTILOCUS SEQUENCE TYPING; PATHOGENICITY; PHENOTYPE; PSEUDOMONAS INFECTION; REGRESSION ANALYSIS; SPAIN; VERY ELDERLY; VIRULENCE;

ANTIINFECTIVE AGENT; BACTERIAL PROTEIN; VIRULENCE FACTOR;

ADULT; AGED; AGED, 80 AND OVER; ANTI-BACTERIAL AGENTS; BACTEREMIA; BACTERIAL PROTEINS; BACTERIAL SECRETION SYSTEMS; DRUG RESISTANCE, BACTERIAL; DRUG RESISTANCE, MULTIPLE, BACTERIAL; FEMALE; GENOTYPE; HUMANS; MALE; MIDDLE AGED; MULTILOCUS SEQUENCE TYPING; PHENOTYPE; PROSPECTIVE STUDIES; PSEUDOMONAS AERUGINOSA; PSEUDOMONAS INFECTIONS; REGRESSION ANALYSIS; SPAIN; VIRULENCE; VIRULENCE FACTORS;

EID: 84922380227     PISSN: 10584838     EISSN: 15376591     Source Type: Journal    
DOI: 10.1093/cid/ciu866     Document Type: Article

References (40)

1. Peña C, Suarez C, Gozalo M, et al. Prospective multicenter study of the impact of carbapenem resistance on mortality in Pseudomonas aeruginosa bloodstream infections. Antimicrob Agents Chemother 2012; 56:1256-72
2. Peña C, Suarez C, Ocampo-Sosa A, et al. Effect of adequate single-drug versus combination antimicrobial therapy on mortality in Pseudomonas aeruginosa bloodstream infections. A post hoc analysis of a prospective cohort. Clin Infect Dis 2013; 57:208-16
3. Chamot E, Boffi El Amari E, Rohner P, Van delden C. Effectiveness of combination antimicrobial therapy for Pseudomonas aeruginosa bacteremia. Antimicrob Agents Chemother 2003; 47:2756-64
4. Kang CI, Kim SH, Kim HB, et al. Pseudomonas aeruginosa bacteremia: risk factors for mortality and influence of delayed of effective antimicrobial therapy on clinical outcome. Clin Infect Dis 2003; 37:745-51
5. Andersson DI. The biological cost of mutational antibiotic resistance: any practical conclusions?. Curr Opin Microbiol 2006; 9:461-5
6. Hattemer A, Hauser A, Diaz M, et al. Bacterial and clinical characteristics of health-care and community-Acquired bloodstream infections due to Pseudomonas aeruginosa. Antimicrob Agents Chemother 2013; 57:3969-75
7. Peña C, Gómez-Zorrilla S, Oriol I, et al. Impact of multidrug resistance on Pseudomonas aeruginosa ventilator-Associated pneumonia outcome: predictors of early and crude mortality. Eur J Microbiol Infect Dis 2013; 32:413-20
8. Engel J, Balachandran P. Role of Pseudomonas aeruginosa type III effectors in disease. Curr Opin Microbiol 2009; 12:61-6
9. Hauser AR. The type III secretion system of Pseudomonas aeruginosa: infection by injection. Nat Rev Microbiol 2009; 7:654-65
10. Woodford N, Turton JF, Livermore DM. Multiresistant gram-negative bacteria: the role of high-risk clones in the dissemination of antibiotic resistance. FEMS Microbiol Rev 2011; 35:736-55
11. Maatallah M, Cheriaa J, Backhrouf A, et al. Population structure of Pseudomonas aeruginosa from five Mediterranean countries: evidence for frequent recombination and epidemic occurrence of CC235. PLoS One 2011; 6:e25617
12. Agnello M, Wong-Beringer A. Differentiation in quinolone resistance by virulence genotype in Pseudomonas aeruginosa. PLoS One 2012; 7:e42973
13. Garey KW, Vo QP, Larocco MT, Gentry LO, Tam VH. Prevalence of type III secretion protein exoenzymes and antimicrobial susceptibility patterns from bloodstream isolates of patients with Pseudomonas aeruginosa bacteremia. J Chemother 2008; 20:714-20
14. Sullivan E, Bensman J, Lou M, Agnello M, Shriner K, Wong-Beringer A. Risk of developing pneumonia is enhanced by the combined traits of fluoroquinolone resistance and type III secretion virulence in respiratory isolates of Pseudomonas aeruginosa. Crit Care Med 2014; 42:48-56
15. Feltman H, Schulert G, Khan S, Jain M, Peterson L, Hauser AR. Prevalence of type III secretion genes in clinical and environmental isolates of Pseudomonas aeruginosa. Microbiology 2001; 147(pt 10):2659-69
16. El-Solh AA, Hattemer A, Hauser AR, Alhajhusain A, Vora H. Clinical outcome of type III Pseudomonas aeruginosa bacteremia. Crit Care Med 2012; 40:1157-63.
17. Hauser AR, Cobb E, Bodi M, et al. Type III protein secretion is associated with poor clinical outcomes in patients with ventilator-Associated pneumonia caused by Pseudomonas aeruginosa. Crit Care Med 2002; 30:521-8.
18. Roy-Burman A, Saver RH, Racine S, et al. Type III secretion is associated with death in lower respiratory and systemic Pseudomonas aeruginosa infections. J Infect Dis 2001; 183:1767-74.
19. Charlson ME, Pompei P, Ales KL, MacKenzie CR. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis 1987; 40:373-83.
20. Le Gall JR, Loirat P, Alperovitch A, et al. A simplified acute physiologic score for ICU patients. Crit Care Med 1984; 12:975-7.
21. Chow JW, Fine MJ, Shlaes DM, et al. Enterobacter bacteremia: clinical features and emergence of antibiotic resistance during therapy. Ann Intern Med 1991; 115:585-90.
22. American College of Chest Physicians/Society of Critical Care Medicine. Consensus Conference Committee. Definitions for sepsis and organ failure and guidelines for use of innovative therapies in sepsis. Crit Care Med 1992; 20:864-74.
23. Kang CI, Kim SH, Park WB, et al. Bloodstream infections caused by antibiotic-resistant gram-negative bacilli: risk factors for mortality and impact of inappropriate initial antimicrobial therapy on outcome. Antimicrob Agents Chemother 2005; 49:760-6.
24. Clinical and Laboratory Standards Institute. Performance standards for antimicrobial susceptibility testing, Vol. 28, No. 3, 18th informational supplement. In: CLSI document M100-S18. Wayne, PA: CLSI, 2008.
25. Magiorakos AP, Srinivasan A, Carey RB, et al. Multidrug resistant, extensively drug-resistant and pandrug-resistant bacteria: an international expert proposal for interim standard definitions for acquired resistance. Clin Microbiol Infect 2012; 18:268-81.
26. Cabot G, Ocampo-Sosa AA, Domínguez MA, et al. Genetic markers of widespread extensively drug-resistant Pseudomonas aeruginosa highrisk clones. Antimicrob Agents Chemother 2012; 56:6349-57.
27. Mulet X, Cabot G, Ocampo-Sosa AA, et al. Biological markers of Pseudomonas aeruginosa epidemic high-risk clones. Antimicrob Agents Chemother 2013; 57:5527-35.
28. Curran B, Jonas D, Grundmann H, Pitt T, Dowson CG. Development of a multilocus sequence typing scheme for the opportunistic pathogen Pseudomonas aeruginosa. J Clin Microbiol 2004; 42:5644-9.
29. Jolley KA, Chan MS, Maiden MC. mlstdbNet-distributed multi-locus sequence typing (MLST) databases. BMC Bioinformatics 2004; 5:86.
30. Beceiro A, Tomás M, Bou G. Antimicrobial resistance and virulence: a successful or deleterious association in the bacterial world?. Clin Microbiol Rev 2013; 26:185-230.
31. Veesenmeyer JL, Hauser AR, Lisboa T, Rello J. Pseudomonas aeruginosa virulence and therapy: evolving translational strategies. Crit Care Med 2009; 37:1777-86.
32. Janjua HA, Segata N, Bernabò P, Tamburini S, Ellen A, Jousson O. Clinical populations of Pseudomonas aeruginosa isolated from acute infections show a wide virulence range partially correlated with population structure and virulence gene expression. Microbiology 2012; 158( pt 8):2089-98.
33. Wareham DW, Curtis MA. A genotypic and phenotypic comparison of type III secretion profiles of Pseudomonas aeruginosa cystic fibrosis and bacteremia isolates. Int J Med Microbiol 2007; 297:227-34.
34. Wong-Beringer A, Wiener-Kronish J, Lynch S, Flanagan J. Comparison of type III secretion system virulence among fluoroquinolone-susceptible and -resistant clinical isolates of Pseudomonas aeruginosa. Clin Microbiol Infect 2008; 14:330-6.
35. Castanheira M, Deshpande LM, Costello A, Davies TA, Jones RN. Epidemiology and carbapenem resistance mechanisms of carbapenemnon-susceptible Pseudomonas aeruginosa collected during 2009-11 in 14 European and Mediterranean countries. J Antimicrob Chemother 2014; 69:1804-14.
36. Cholley P, Thouverez M, Hocquet D, Van der Mee-Marquet N, Talon D, Bertrand X. Most multidrug-resistant Pseudomonas aeruginosa isolates from hospitals in eastern France belong to a few clonal types. J Clin Microbiol 2011; 49:2578-83.
37. Edelstein MV, Skleenova EN, Shevchenko OV, et al. Spread of extensively resistant VIM-2-positive ST235 Pseudomonas aeruginosa in Belarus, Kazakhstan, and Russia: a longitudinal epidemiological and clinical study. Lancet Infect Dis 2013; 13:867-76.
38. Kim MJ, Bae IK, Jeong SH, et al. Dissemination of metallo-β-lactamaseproducing Pseudomonas aeruginosa of sequence type 235 in Asian countries. J Antimicrob Chemother 2013; 68:2820-4.
39. Viedma E, Juan C, Acosta J, et al. Nosocomial spread of colistin-onlysensitive sequence type 235 Pseudomonas aeruginosa isolates producing the extended-spectrum beta-lactamases GES-1 and GES-5 in Spain. Antimicrob Agents Chemother 2009; 53:4930-3.
40. Lu Q, Eggimann P, Luyt CE, et al. Pseudomonas aeruginosa serotypes in nosocomial pneumonia: prevalence and clinical outcomes. Crit Care 2014; 18:R17.